• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Merck Kgaa ADR (OP: MKKGY )

    35.73 -0.30 (-0.83%)
    Streaming Delayed Price Updated: 10:05 AM EDT, Jul 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Merck Kgaa ADR

    Pfizer Clears Required Regulatory Hurdles To Complete $43B Seagen Acquisition
    Pfizer Inc (NYSE: PFE)  
    Via Benzinga
    Merck Germany's Two Pivotal Trials Flunk In Multiple Sclerosis
    Merck KGaA (OTC: MKGAF) (OTC:  
    Via Benzinga
    Life Sciences Player Repligen's Strategic European Acquisition - What It Means for Investors
    Repligen Corporation (NASDAQ: RGEN) agreed to acquire Sweden-based privately-held Metenova.  
    Via Benzinga
    Merck Germany Reports 5% Decline In Q2 Sales, Expects More Decline In 2023
    Merck KGa Germany (OTC: MKGAF) (OTC: MKKGY) reported  
    Via Benzinga
    Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List
    The World Health Organization (WHO) published the new editions of the Model Lists of Essential Medicines (EML) and Essen 
    Via Benzinga
    Germany's Merck To Launch Semiconductor Base In China
    Via Benzinga
    Abcam Downgrade: Analyst Trims Expectations Amid Activist Investor Engagement and Potential Bid Anticipation
    RBC Capital Markets has downgraded Abcam PLC (NASDAQ: ABCM) from Outperform to Sector Perform with a price target of $22,  
    Via Benzinga
    Analyst Says Nektar Therapeutics' Rezpeg Prioritization Likely to Spark Investor Questions
    Via Benzinga
    FDA Issues Partial Clinical Hold On Merck Germany's Multiple Sclerosis Study
    Via Benzinga
    Merck Germany Regains Exclusive Global Rights To Cancer Drug From Pfizer
    Via Benzinga
    Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval
    Via Benzinga
    With Upcoming Ovarian Cancer Data, Analyst Sees 100% Upside For Mersana Therapeutics
    Via Benzinga
    PDS Biotech, Merck Germany Enter Licensing Pact For Investigational Cancer Treatment
    Via Benzinga
    Mersana Inks Cancer Therapy Development Deal With Merck Germany
    Via Benzinga
    SpaceX Starlink's New In-Flight Connectivity Service, Amazon's NY Workers Reject Union, Celsius Network Faces Several Federal Investigations: Top Stories Wednesday, Oct. 19
    Reuters US Lawmakers Plan Hearing On Kroger, Albertsons' $25B Merger 
    Via Benzinga
    Germany's Merck Slapped With Formal French Investigation Related To Its Thyroid Drug
    The French court is reportedly investigating Germany-based Merck KGaA (OTC: MKKGY), saying the company provided misleading information regarding its thyroid drug product Levothyrox. 
    Via Benzinga
    PDS Biotech Highlights Expanded Data From PDS0101 Triple Combination Trial In HPV-Positive Cancers
    Via Benzinga
    TSM Looks To Hire Over 8,000 People In 2022
    Taiwan’s top two chipmakers plan to hire over 10,000 engineers in 2022 to bolster their aggressive expansion plans and maintain their technological edge, Financial... 
    Via Benzinga
    Despite Palantir’s Impressive Deals, Its Losses and Valuation Make It Unappetizing
    Amid continued questions about the profitability and the competitive advantages of Palantir in a crowded field, PLTR stock remains a sell. 
    Via InvestorPlace
    The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill Supply Deal With US, Roche's Spark Therapeutics Reports Positive Gene Therapy Readout, EDAP Earnings
    Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Roche's Spark Subsidiary Reports Positive Phase 1/2 Data For Hemophilia... 
    Via Benzinga
    GlaxoSmithKline, Merck KGaA End $4B Cancer Drug Pact
    Merck KGaA (OTC: MKGAF) and GlaxoSmithKline Plc (NASDAQ: GSK) have ended their $4 billion collaboration on cancer treatment, bintrafusp alfa. Merck said... 
    Via Benzinga
    Nektar, Merck Germany, Pfizer Join Forces For Mid-Stage Bladder Cancer Study
    Nektar Therapeutics Inc (NASDAQ: NKTR) has entered into a new oncology clinical collaboration with Merck KGaA (OTC: MKGAF) and Pfizer Inc (NYSE... 
    Via Benzinga
    Merck KGaA Pulls Plug On GSK-Partnered Cancer Drug Trial
    Merck KGaA's (OTC: MKGAF) announced that a Phase 2 trial of bintrafusp alfa had been discontinued, as an independent data monitoring committee has determined the... 
    Via Benzinga
    Sutro Biopharma Receives Undisclosed Milestone Payment Under Bispecific ADC Collaboration with Merck
    Sutro Biopharma Inc (NASDAQ: STRO) has received a milestone payment under its collaboration and license agreement with the healthcare division of Merck KGaA... 
    Via Benzinga
    Immutep, Merck Germany Team Up for Eftilagimod/Bintrafusp Combo Trial In Solid Tumors
    Immutep Limited (NASDAQ: IMMP) has announced a new collaboration and supply agreement with Germany-based Merck KGaA (OTC: MKGAF) for a Phase 1/2a INSIGHT... 
    Via Benzinga
    Gene Therapy Player Vera Therapeutics Prices IPO Well Below Range At $11/Share
    Vera Therapeutics Inc has priced its 4.35 million share IPO at $11 per share, well below its targeted range of $14 to $16, raising $47.58 million in gross proceeds. The... 
    Via Benzinga
    Topics Initial Public Offering
    Exposures Securities Market
    MERCK KGAA (MKKGY) Q1 2021 Earnings Call Transcript
    MKKGY earnings call for the period ending March 31, 2021. 
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    UK's NICE Provisionally Rejects Coverage Of Pfizer-Merck KGaA's Bavencio As First-Line Therapy For Bladder Cancer
    England’s drug-cost watchdog has shown a cold-shoulder to Pfizer Inc (NYSE: PFE) and Merck KGaA’s (OTCMKTS: MKGAF) Bavencio (avelumab) as... 
    Via Benzinga
    The Daily Biotech Pulse: Negative Regulatory Tidings For Provention Bio, Celcuity Soars On In-licensing Deal, 2 IPOs
    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 8) Aclaris Therapeutics, Inc... 
    Via Benzinga
    Novartis Taps Artios In Discovery Pact To Enhance Radioligand Portfolio
    Novartis AG (NYSE: NVS) has struck a deal with UK-based Artios Pharma to access DNA damage response (DDR) targets that can potentially enhance its radioligand... 
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.